Stock Events

Stock Events

Scandion Oncology A/S 

€0.014000
0
+€0.00+2.94%Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
0.0162
52W Low
0.0002
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. develops oncology drugs that directly compete in the cancer treatment market, overlapping with Scandion Oncology's focus.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb is involved in developing cancer therapies, potentially competing with Scandion Oncology's drug development pipeline.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a broad portfolio of oncology drugs that could compete with treatments being developed by Scandion Oncology.
Novartis
NVS
Mkt Cap303.67B
Novartis AG focuses on innovative healthcare solutions including oncology, which competes with Scandion Oncology's cancer treatment research.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG specializes in biopharmaceuticals, including oncology, which is a direct market competitor to Scandion Oncology.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC has a strong focus on the development of cancer drugs, competing in the same space as Scandion Oncology.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. develops therapeutic solutions in oncology, competing with Scandion Oncology's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. operates in the oncology sector, providing competitive pressure to Scandion Oncology's market.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company produces oncology drugs, which could compete with the cancer treatments developed by Scandion Oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, including oncology, competing with Scandion Oncology's research and products.

About

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Show More
CEO
Mr. Jan Stenvang M.S., Ph.D.
Employees
4
Country
Denmark
ISIN
DK0061031895
WKN
000A2N9BV

Listings

STU
DE
8VY.STU

0 Comments

Share your thoughts

FAQs

What is Scandion Oncology A/S stock price today?▼
The current price of 8VY.STU is €0.01 EUR — it has increased by +2.94% in the past 24 hours. Watch Scandion Oncology A/S stock price performance more closely on the chart.
What is Scandion Oncology A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Scandion Oncology A/S stocks are traded under the ticker 8VY.STU.
How many employees does Scandion Oncology A/S have?▼
As of November 2, 2026, the company has 4 employees.
In which sector is Scandion Oncology A/S located?▼
Scandion Oncology A/S operates in the Health & Wellness sector.
When did Scandion Oncology A/S complete a stock split?▼
Scandion Oncology A/S has not had any recent stock splits.
Where is Scandion Oncology A/S headquartered?▼
Scandion Oncology A/S is headquartered in Copenhagen, Denmark.